Intimation regarding completion of US FDA Inspection

August 14, 2026 BSE Limited The National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Exchange Plaza, Street, Mumbai – 400 001 Bandra Kurla Complex Bandra (E), Mumbai – 400 001 Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ Dear Sir/Madam, Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 We wish to inform you that the United States Food and Drug Administration (“US FDA”) has inspected our Unit 3 manufacturing facility, located at Gaddapotharam village, Jinnaram, Sangareddy District, from 10th to 14th of August 2026. At the conclusion of the inspection, the US FDA issued a Form 483 with one observation. The observation pertains to procedural improvements in water and environmental monitoring to include new organisms beyond those listed in the United States Pharmacopeia (USP). The Company will submit its response to the US FDA within the stipulated timelines. This is for your information and records. Thanking you Yours Sincerely, For Neuland Laboratories Limited Sarada Bhamidipati Company Secretary